Spire Healthcare Group (LON:SPI) Stock Price Down 21.4% After Analyst Downgrade

Shares of Spire Healthcare Group plc (LON:SPI) were down 21.4% during mid-day trading on Thursday after Deutsche Bank Aktiengesellschaft lowered their price target on the stock from GBX 320 to GBX 300. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock. Spire Healthcare Group traded as low as GBX 169 ($2.18) and last traded at GBX 176.40 ($2.28). Approximately 3,426,506 shares changed hands during mid-day trading, an increase of 447% from the average daily volume of 626,257 shares. The stock had previously closed at GBX 224.50 ($2.90).

Spire Healthcare Group Stock Down 6.0 %

The stock has a market capitalization of £711.58 million, a price-to-earnings ratio of 25.22, a PEG ratio of 1.06 and a beta of 0.96. The business has a fifty day moving average of GBX 227.28 and a 200 day moving average of GBX 229.74. The company has a debt-to-equity ratio of 62.25, a current ratio of 0.70 and a quick ratio of 0.74.

Spire Healthcare Group (LON:SPI) last released its quarterly earnings results on Thursday, March 6th. The company reported GBX 8.80 ($0.11) EPS for the quarter. Spire Healthcare Group had a return on equity of 3.82% and a net margin of 1.96%. As a group, equities analysts predict that Spire Healthcare Group plc will post 15.6634747 earnings per share for the current year.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.